^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Cutaneous Melanoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
11/25/2020
Excerpt:
Melanoma: Cutaneous...Systemic Therapy for Metastatic or Unresectable Disease...First-line therapy; Other recommended regimens...Pembrolizumab/low-dose ipilimumab (category 2B) added as an option...Second-line or subsequent therapy; Systemic therapy; Preferred regimens...Pembrolizumab/low-dose ipilimumab or tumors that have progressed after prior anti-PD-1 therapy added as an option.
